RA
COCHW icon

RiverPark Advisors’s Envoy Medical Warrant COCHW Stock Holding History

RiverPark Advisors’s Portfolio COCHW Stock Details COCHW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,913
Closed -$5K – 215
2021
Q3 		$5K Buy
+7,913
New +$6.43K ﹤0.01% 174

Other funds holding COCHW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
HHAM
HITE Hedge Asset Management Braintree, Massachusetts $1.77B AUM 38.67% 1-Year Est. Return

RiverPark Advisors's COCHW Position: Q4 2021 in Review

RiverPark Advisors sold out of Envoy Medical Warrant (COCHW) in Q4 2021, closing a stake of 7,913 shares — an estimated $5K sold.

RiverPark Advisors first reported a position in COCHW in Q3 2021 and held it in 1 quarter. The position peaked at $5K in Q3 2021. 57 funds tracked by Wall St. Rank hold COCHW as of Q4 2021.

  • RiverPark Advisors reported no remaining Envoy Medical Warrant position as of Q4 2021 after selling out during the quarter.
  • RiverPark Advisors sold 7,913 Envoy Medical Warrant shares in Q4 2021, an estimated $5K.
  • RiverPark Advisors first reported a position in Envoy Medical Warrant in Q3 2021 and held it in 1 quarter.
  • RiverPark Advisors's Envoy Medical Warrant position peaked at $5K in Q3 2021.
  • 57 funds tracked by Wall St. Rank held Envoy Medical Warrant as of Q4 2021.

Based on RiverPark Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.